Here we show that neurexins directly bind to the extracellular domains of GABAA-receptors, and specifically inhibit postsynaptic GABAA-receptors by a neuroligin-independent mechanism. We made six principal observations
First, neurexins directly interact with GABA
Aα1-receptors, as shown by binding of recombinant IgNrx-2β to endogenous GABA
Aα1-receptors in brain and to transfected GABA
Aα1-receptors in HEK293 cells; co-immunoprecipitation of neurexin-1β with GABA
Aα1-receptors from transfected HEK293 cells; pulldown of endogenous brain neurexin/GABA
Aα1-receptor complexes and of recombinant neurexin/GABA
Aα1-receptor complexes with the CASK PDZ-domain; and measurements of the direct interaction of the purified extracellular domains of neurexin and GABA
A α1-receptors (, ,
S6 and S7).
Second, increasing neurexin expression decreases GABAergic but not glutamatergic synaptic transmission. This conclusion is based on lentiviral overexpression of neurexins (), transfection of neurexins ( and ), and addition of recombinant neurexin to the medium (). Neurexins have a large effect (>2-fold decrease in IPSCs in most assays) that is specific (no changes in EPSCs, no decreases in synapse numbers or major changes in neuronal protein composition; – and
S1–S5). Possibly most unexpected is the potency of recombinant neurexin that specifically suppressed IPSCs at only 0.5 μM (). All neurexins tested had a similar effect that was independent of alternative splicing at site #4 (–).
Third, neurexins act via an extracellular mechanism on the neuronal surface. This was shown by the effectiveness of recombinant neurexin added to the culture medium (), and of over-expressed neurexin-2β
ΔCt which lacks a cytoplasmic tail (). In contrast, Ct-neurexin-1β composed of only the common neurexin cytoplasmic tail and transmembrane region was inactive (), as was mutant neurexin that is retained intracellularly (). Moreover, a neurexin-2β mutant that is retained in the ER is inactive, and postsynaptic knockdown of neurexins has no effect ( and
S4).
Fourth, neurexins inhibit GABAergic responses independent of neuroligins. Co-transfection of neurexins with neuroligin-1 or neuroligin-2 did not ablate the inhibitory effect of neurexins on GABAergic synaptic transmission (); neurexin-2β still inhibited GABAergic transmission in KO neurons lacking neuroligin-2, the only neuroligin specifically involved in inhibitory synaptic transmission (
Chubykin et al., 2007), or neuroligin-3 (); recombinant neurexin added to cultured neurons had the same effect as transfected neurexins (), which would not be expected if the overexpressed neurexins sequestered neuroligins in the neurons; a neurexin mutant that does not bind to neuroligins still bound to GABA
A-receptors, and still inhibited GABAergic synaptic transmission ( and ); and a neurexin-2β mutant that is retained in the ER of neurons where it still binds to neuroligins did not decrease inhibitory synaptic strength (). Note that the experiments with the various splice variants of neurexins and their mutants also rule out a participation of the recently discovered interaction of neurexins with LRRTMs (
Ko et al., 2009;
de Wit et al., 2009).
Fifth, neurexins likely act by binding directly to GABAAα1-receptors on the cell surface. This conclusion is inherent to the findings we made in neurons after addition of recombinant neurexin to the medium () and after transfection of various neurexin mutants (–), and further amplified by the finding that transfection of neurexin-2β into GABAA-receptor expressing HEK293 cells or addition of IgNrx-2β to such cells suppressed GABA-induced currents in these non-neuronal cells ().
Sixth, finally, an excess of neurexins does not impair the functions of existing GABAergic sites – receptors and/or synapses – but prevents the developmental increase of GABAergic synaptic transmission in cultured neurons. Both for neurexin-transfected neurons and for untransfected neurons treated with recombinant neurexin, the neurexin “froze” the neuron in the state it was at the point at which the treatment was started ( and ).
Relation to previous studies
Our study appears to contradict nearly all previously published reports on neurexins, including many from our own laboratory. As described below, however, some of these contradictions may be more apparent than real.
We observed that excess neurexins selectively decrease inhibitory synapses, instead of promoting formation of excitatory synapses as suggested in studies using co-cultures of neurons with transfected non-neuronal cells (
Graf et al., 2004;
Nam and Chen, 2005). However, the lack of an effect of neurexins on synapse formation is consistent with the finding that deletion of α-neurexins does not decrease the number of excitatory synapses, and only moderately decreases the number of inhibitory synapses (
Missler et al., 2003).
Moreover, we detected an apparently postsynaptic effect of neurexins, whereas neurexins are thought to function primarily presynaptically. However, our study shows that postsynaptically expressed neurexins act in the postsynaptic neuron only after transport to the cell-surface, and thus may in fact mimic a presynaptic effect.
Furthermore, we propose that the observed effect of neurexins is independent of neuroligins, whereas most processes connected to neurexins can be accounted for by their binding to neuroligins. Indeed, because neurexins can be observed postsynaptically, they were speculated to be postsynaptic regulators of neuroligins (
Taniguchi et al., 2007). However, there is no reason why neurexins should not bind to other proteins besides neuroligins (e.g., see
Ko et al., 2009a;
de Wit et al., 2009), and neuroligins also have neurexin-independent functions (
Ko et al., 2009b).
Finally, our current results differ from those obtained with α-neurexin KO mice (
Missler et al., 2003;
Kattenstroth et al., 2004; Zhang et al., 2006). Here, we observed a selective effect of neurexins on inhibitory synapses (i.e., it is not simple synapse damage) that is mediated by an extracellular cell-surface interaction of neurexins with postsynaptic neurons. In contrast, in the KO studies we found an essential function of α-neurexins in organizing neurotransmitter release from all presynaptic nerve terminals. However, a specific change in inhibitory synaptic transmission would have been unobservable in α-neurexin KO mice (
Missler et al., 2003) because these mice exhibit an overwhelming impairment in neurotransmitter release which would have occluded a separate facilitation of inhibitory synapses. Moreover, the continued expression of β-neurexins in these mice may have prevented manifestation of an inhibitory synapse phenotype. Thus, despite their differences, it seems likely that the two approaches revealed distinct parts of the overall picture of neurexin function.
Physiological significance
Our data suggest that neurexins decrease GABAergic synaptic transmission by direct binding to GABA
A-receptors on the cell surface at the synapse, and that neurexins act by impeding the functional maturation of GABAergic synapses, not their initial formation. Thus, the effects of excess neurexins observed in our experiments may reflect a function of neurexins in regulating GABAergic synapse maturation. We propose that this newly observed activity is one facet of multiple actions of neurexins at synapses, and that presynaptic neurexins likely constitute master regulators of synapse maturation (or validation) via trans-synaptic interactions with an array of postsynaptic targets, which are only now slowly being discovered, as exemplified by the identification of LRRTMs as novel neurexin ligands (
Ko et al., 2009a;
de Wit et al., 2009). Teasing apart the physiological importance of the various interactions will require definition of neurexin mutations that specifically and selectively impair one interaction without affecting others, since the example of the α-neurexin KO mice has already demonstrated that global ablation of neurexin expression is too blunt an instrument in order to define the full range of neurexin functions. However, the present observations uncovering a very robust action of neurexins on postsynaptic GABA
A-receptors extend and expand the emerging concept that neurexins function not in the initial establishment of synapses, but in shaping their properties, in their maturation. A key observation in this regard is the developmental effect of neurexins in the assays described here, which clearly shows that once synapses are formed, they are immune from the effect of overexpressed neurexins. Since synapses are likely continuously formed throughout adult life, this developmental action naturally continues beyond the actual development of the organism, and corroborates the notion of neurexins as key regulators of synaptic properties.
We propose that the effect of neurexins on postsynaptic GABA
A-receptors observed here is likely trans-synaptic. However, independent of whether the interaction of neurexins with GABA
A-receptors is postsynaptic or trans-synaptic, our findings may shed light on the role of neurexins in cognitive diseases such as autism, addiction, and schizophrenia (
Szatmari et al., 2007;
Kim et al., 2008;
Yan et al., 2008;
Marshall et al., 2008;
Zahir et al., 2008;
Kirov et al., 2008;
Rujescu et al., 2008;
Walsh et al., 2008;
Hishimoto et al., 2007;
Lachman et al., 2007; reviewed in
Südhof, 2008). In these disorders, changes in inhibitory synaptic transmission are thought to play a major role. Specifically, alterations in the levels of GABA and GABA-receptors (including GABA
Aα1) in autistic patients, and mutations in genes expressing GABA receptor subunits (
Collins et al., 2006;
Fatemi et al., 2008) suggest that the GABAergic system may be centrally involved in autism. Additionally, extensive studies have indicated that mutations in GABA
Aα1-receptor genes are associated with schizophrenia (
Petryshen et al., 2005). In view of the fact that deletions of neurexin-1 α are also associated with autism and schizophrenia (
Szatmari et al., 2007;
Kim et al., 2008;
Yan et al., 2008;
Marshall et al., 2008;
Zahir et al., 2008;
Kirov et al., 2008;
Rujescu et al., 2008;
Walsh et al., 2008;
Hishimoto et al., 2007;
Lachman et al., 2007), and that neurexin-1α KO mice exhibit traits resembling schizophrenia (
Etherton et al., 2009), our observation that neurexins physically and functionally interact with GABA
A-receptors raise the tantalizing possibility that alterations in GABAergic synaptic transmission may contribute to a convergent mechanism for increasing the risk of autism and schizophrenia.